Document is current
Any future updates will be listed below
-
Authors
Liao, Mingxiang
Jeziorski, Krzysztof G.
Tomaszewska-Kiecana, Monika
Láng, István
Jasiówka, Marek
Skarbová, Viera
Centkowski, Piotr
Ramlau, Rodryg
Górnaś, Maria
Lee, John
Edwards, Sarah
Habeck, Jenn
Nash, Eileen
Grechko, Nikolay
Xiao, Jim J. https://orcid.org/0000-0003-3632-2012
-
Funding
Funding for this research was provided by:
Clovis Oncology
- License Information
-
More Information
Article History
Received: 4 May 2021
Accepted: 23 July 2021
First Online: 9 August 2021
Declarations
:
: RR has served in a consulting or advisory role for Pfizer, Takeda, Boehringer Ingelheim, Roche, MSD, Novartis, and Bristol-Myers Squibb. EN has served in a consulting or advisory role for Bay Trials Unlimited, LLC. ML, JL, SE, JH, NG, and JX are employees of Clovis Oncology and may own stock or have stock options in that company. KGJ, MT-K, IL, MJ, VS, PC, and MG declare no conflict of interest.
: The study protocol was approved by the Independent Ethics Committee of each institution. The study was conducted in compliance with the International Council for Harmonization Guideline for Good Clinical Practice, Food and Drug Administration regulatory requirements, and the Declaration of Helsinki.
: All patients signed the informed consent forms prior to entering the study.
: All authors gave consent for publication.
